80results about "Veterinary vaccine" patented technology

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

An immunogenic fusion protein used for active immunization or a bivalent vaccine in the treatment of atopic dermatitis (AD) in a subject and a method thereof. The immunogenic fusion protein includes a IL31 polypeptide and at least one substance P polypeptide (SP). The invention is particularly useful for treating and / or preventing AD and symptoms related to AD including pruritus in mammals.

The present invention provides recombinant viral vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant viral vectors, polyvalent vaccines comprising the recombinant viral vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant viral vectors.

The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.

We provide a vaccine against C. chauvoei. [Solution] A vaccine comprising the C chauvoei component and additional cctA protein is provided. Methods for producing and using the vaccine are also provided.

The present invention provides a method for constructing a circular RNA and a vaccine against feline FIPV. The method relates to a pharmaceutical formulation, the pharmaceutical formulation comprising a nucleic acid fragment, the nucleic acid fragment being a circular RNA comprising a first nucleic acid fragment and a second nucleic acid fragment, the first nucleic acid fragment encoding the M protein of feline infectious peritonitis virus, the second nucleic acid fragment encoding the N protein of feline infectious peritonitis virus, and the first nucleic acid fragment being ligated to or not ligated to the second nucleic acid fragment.

The present invention relates to a combination of a first vaccine containing a non-replicating immunogen of Erysipelothrix rhusiopathiae and a non-replicating immunogen of porcine parvovirus, and a second vaccine containing a non-replicating immunogen of Leptospira bacteria, for use in the prophylactic treatment of pigs against Erysipelothrix rhusiopathiae infection, porcine parvovirus infection, and Leptospira bacteria infection, by injecting the first vaccine and the second vaccine separately into the dermis at a first injection site and a second injection site, respectively, in association with each other.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and / or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gingivalis in a subject, and uses thereof.

The disclosure relates to the identification and characterisation of a cytotoxin from Campylobacter hepaticus and use thereof for treating Spotty Liver Disease (SLD) in avian animals.

The present invention relates to a Babesia antigen comprising at least a portion of a gametocyte HAPLESS2 / GCS1 (HAP2) protein, vectors and cells expressing such antigen, compositions and kits comprising such antigens, and methods of using such antigens to interfere with the Babesia transmission by competent ticks.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

The present invention provides a chimeric or fusion protein for inducing an immune response to P. gulae, the protein comprising a first polypeptide and a second polypeptide, wherein: A) the first polypeptide comprises or consists of an amino acid sequence of the active site of an Arg- or Lys-gingipain of P. gulae, or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of: the amino acid sequence of a DUF2436 domain of a P. gulae Arg- or Lys-gingipain; and the amino acid sequence of an adhesin domain of an Arg- or Lys-gingipain of P. gulae.

Implementations of an anti-tick vaccine composition may include one or more conserved tick proteins from a tick species; and one or more conserved outer membrane proteins of an endosymbiont of the tick species.

The application belongs to the field of biological medicine, and provides a method for promoting transient overexpression of exogenous genes in fish based on PEI40000 and application of PEI40000 in enhancing protection rate of fish hemorrhagic disease virus DNA vaccine. The PEI40000 reagent provided by the application is convenient to store and stable in property; preparation and application operation are simple; the reagent can be directly added into a culture medium containing serum; the cost performance is high, and the reagent is suitable for large-scale transfection experiments; the application verifies that the method significantly promotes expression of an exogenous plasmid in fish, and makes the expression time effect have a higher overexpression level within 1-10 days; and it is also clear that the application significantly enhances the protection effect of the fish hemorrhagic disease virus DNA vaccine, and significantly improves the survival rate of diseased fish, and the effect is more significant than that of the common adjuvant in the prior art, and the application can become an effective adjuvant for various DNA vaccines, and has a wide application prospect.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.

A vaccine composition comprising a virus antigen wherein the composition comprises less than 5% serum, wherein the virus antigen is a whole virus or derived from a whole virus. the vaccine composition reduces, prevents or avoids cross-stitch spinal deformity in the treated animal

Proposed are a foot-and-mouth disease vaccine composition including recombinant foot-and-mouth disease viruses and an antigen isolated and purified from the viruses. In the early stages of vaccination, a humoral immune response is simultaneously induced through the induction of a robust cellular immune response, while in the presence of maternally-derived antibodies (MDAs), B cell receptors are stimulated. Through this, it is possible to provide the vaccine composition that enables active immunity and overcomes the interference of the maternally-derived antibodies and to provide a method of preventing or treating foot-and-mouth diseases using the same composition.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions.

The present invention relates to a vaccine containing a non-replicating Leptospira immunogen for use in the prophylactic treatment of pigs against Leptospira infections by injecting a first vaccine into the dermis of the pig.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).